Black Diamond Therapeutics’ BDTX lead clinical-stage program, silevertinib (formerly BDTX-1535), is a brain penetrant, fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor ...

March 17, 2009 (Hollywood, Florida) — The management of dermatologic toxicities associated with the use of epidermal growth-factor-receptor (EGFR) inhibitors in cancer patients is in a nascent stage ...

Adding the VEGF inhibitor ramucirumab (Cyramza) to the EGFR inhibitor osimertinib (Tagrisso) slowed progression of untreated EGFR-positive non-small cell lung cancer (NSCLC) by 9 months compared with ...

The acquisition aims to accelerate the development of targeted therapies for EGFR mutant NSCLC patients globally.

Cancer-Control Outcomes of Patients With Metastatic Castration-Resistant Prostate Cancer With BRCA Gene or Tumor Suppressor Mutations Undergoing 177-Lutetium Prostate-Specific Membrane Antigen ...

TKIs under active clinical investigation are mostly derived from quinazoline, and are low molecular weight synthetic molecules that block the magnesium-ATP-binding pocket of the intracellular tyrosine ...

The mistaken activation of certain cell-surface receptors contributes to a variety of human cancers. Knowing more about the activation process has led researchers to be able to induce greater ...

Overall survival results reported for the Phase III CTONG1104 trial showed benefit in terms of progression-free but not overall survival (OS). In this study, gefitinib was employed for 24 months ...

Background: Treatment options for lung cancer patients with epidermal growth factor receptor (EGFR) mutations are limited after tyrosine kinase inhibitor (TKI) resistance. We aimed to evaluate the ...

Several cancer types are treated with epidermal growth factor receptor (EGFR)-targeting agents (EGFR inhibitors), but this treatment is associated with dermal toxicity in up to 90% of cases, where 80% ...